ArticlePLOS global public health2025
Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.Frontiers in cellular and infection microbiology · 2026Article
- Development of a point-of-care dual one-step recombinase-aided PCR assay for rapid identification ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO recommends the bedaquiline, pretomanid, and linezolid (BPaL) regimen with the additional fluoroquinolone antibiotic moxifloxacin (BPaLM) for initial treatment of multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB). However, fluoroquinolone drug susceptibility testing (DST) coverage for MDR/RR-TB is only around 55% globally, and the efficacy of moxifloxacin may be compromised in settings with high fluoroquinolone resistance. We extended a previous Markov cohort model to assess the cost-effectiveness of the empirical use of BPaLM as a replacement for BPaL for the treatment of MDR/RR-TB in four high MDR/RR-TB burden countries. We obtained fluoroquinolone resistance rates in these countries from WHO surveillance data and parameterised treatment efficacy from recent trial results. We performed scenario analyses across varying fluoroquinolone resistance prevalence and performed Monte Carlo simulations to generate uncertainty intervals for our primary cost-effectiveness estimates. BPaLM incurred higher costs than BPaL but averted more disability-adjusted life years, with incremental cost-effectiveness ratios below 50% of each country's 2019 GDP per capita. This finding remained robust across a feasible fluoroquinolone resistance prevalence range (0-70%). In the absence of fluoroquinolone DST, empirical use of BPaLM resulted in $58 (interquartile range: $49-$73), $32 (IQR: $23-$53), $35 (IQR: $28 - $51), $174 (IQR: $161 - $209) per DALY averted in Georgia, India, the Philippines, and South Africa respectively. Our findings support the empirical use of BPaLM as a potential replacement for BPaL for the treatment of MDR/RR-TB in the absence of fluoroquinolone DST, even if fluoroquinolone resistance prevalence were to increase, reinforcing recent WHO recommendations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.